News & media

FDA Clears clonoSEQ to Detect MRD in Chronic Lymphocytic Leukemia

ClonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells.

Continue reading

Experts Outline Best Practices in the Treatment of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that can be treated to…

Continue reading

Experts Discuss Treatment Advances for Chronic Lymphocytic Leukemia

CLL is a rare cancer of the blood and bone marrow, and although it is difficult to treat many…

Continue reading

Immunoglobulin Abnormalities Do Not Affect Overall Survival in CLL, Study Finds

While immunoglobulin abnormalities appear to shorten treatment-free survival periods, they do not…

Continue reading

CLL Advocates NZ Newsletter Issue 2

Welcome to our first CLL Advocates newsletter. Like many organisations, we weren’t able to…

Continue reading

Genetic Prognostic Factors in CLL Treated With Novel Compounds

Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus…

Continue reading

CLL Experts Favor Social Distancing, but Vary on Treatment Continuation Amid Pandemic

Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid…

Continue reading

Dr. Davids on the Potential Utility of Frontline Ibrutinib/Umbralisib in CLL and MCL

Matthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib…

Continue reading

A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Continue reading

Age, Recent Treatment, Appear to Influence Severity of COVID-19 in Patients With CLL

Older patients with chronic lymphocytic leukemia (CLL) appear to be more likely to have severe…

Continue reading

Dr. Ghia on the Shift From Chemotherapy to Novel Agents in CLL

Paolo Ghia, MD, PhD, discusses how use the of chemotherapy is decreasing in favor of novel agents…

Continue reading

Tool appears to predict need for treatment in asymptomatic, early-stage CLL

A novel prognostic tool appeared to predict the need for treatment among patients with…

Continue reading

CLL and MCL Survival Benefit From Umbralisib Plus Ibrutinib Holds Up in 4-Year Follow-Up

In an interview with Targeted Oncology, Matthew Davids, MD, MMSc, discussed the long-term follow-up…

Continue reading

Long-Term Results of Ibrutinib/Umbralisib Show Efficacy in CLL and MCL

Matthew S. Davids, MD, discusses the long-term follow-up of a phase 1/1b trial for patients with…

Continue reading

Changes in Management of CLL Due to COVID-19 Noted in Italy

The management of CLL, including delays in work-up and treatment, and modifications to clinical…

Continue reading

Dr. Al-Sawaf on Fixed-Duration Versus Continuous Treatment in CLL

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment…

Continue reading

Specialty Pharmacists Have Broad Responsibilities in Chronic Lymphocytic Leukemia

AT JUST 1.2%, chronic lymphocytic leukemia (CLL) represents a small percentage of all new cancer…

Continue reading

Discontinuation of Venetoclax Impacts Outcomes of Rituximab Combination in CLL

In an interview with Targeted Oncology, Anthony Mato, MD, discussed the findings of venetoclax…

Continue reading

CLL Advocates NZ Newsletter Issue 1

Welcome to our first CLL Advocates newsletter. Like many organisations, we weren’t able to…

Continue reading

Three-Drug Combo Promising Against High-Risk CLL

For patients with high-risk chronic lymphocytic leukemia (CLL), first-line therapy with a triple…

Continue reading

Chemotherapy-Free Regimen Consisting of 3 Novel Agents for Previously Untreated, Poor Prognosis CLL

Nearly 60% of evaluable patients with previously untreated, chronic lymphocytic leukemia (CLL)…

Continue reading

Dr. Flinn on the Role of BTK Inhibitors in CLL

Ian W. Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research…

Continue reading

‘CLL flares’ reported after stopping ibrutinib

Patients with ibrutinib-resistant CLL should remain on the BTK inhibitor until immediately before…

Continue reading

Durable disease control achieved with BTKi salvage therapy in patients with CLL

Patients with chronic lymphocytic leukaemia (CLL) who progress on venetoclax can achieve durable…

Continue reading

Gillian Corbett

A current overview of medications in the treatment of CLL in New Zealand

A talk presented to the CLL Advocates NZ Board of Trustees on 7 May 2020 by Dr Gillian Corbett…

Continue reading

Study Findings Support Long-Term Efficacy and Safety of Acalabrutinib in R/R CLL

Long-term follow-up of a phase 1/2 study demonstrated durable efficacy and safety of acalabrutinib…

Continue reading

Coronavirus: Separating Fact From Fiction for CLL Patients

“We're learning every day, and we're modifying and adjusting based on what we learn,” says Dr.…

Continue reading

COVID-19’s Impact on How Patients with CLL, Myeloma Have Received Treatment

In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 &…

Continue reading

How COVID-19 Has Impacted Clinical Trials for Chronic Lymphocytic Leukemia

The COVID-19 Pandemic has changed immediate treatment for patients with chronic lymphocytic…

Continue reading

New Research Shows Real-World Track Record of Common CLL Therapies

A new study based on treatment of patients with chronic lymphocytic leukemia (CLL) in mostly…

Continue reading